Biweekly dosing of efsubaglutide alfa maintains glycaemic and continuous glucose monitoring control in type 2 diabetes: A randomised multicentre trial
Over 12 weeks, efsubaglutide alfa 3 mg Q2W provided glycaemic and CGM benefits comparable to 1 mg QW with favourable tolerability. These findings support the feasibility of a biweekly regimen as an alternative to weekly dosing; larger, longer-duration confirmatory trials in more diverse populations are warranted.
Authors
- Qinghua Wang (ORCID: https://orcid.org/0000-0002-6478-0988)
- Jianping Yao (ORCID: https://orcid.org/0000-0002-9972-5655)
- Hongyan Shu
- Li Li (ORCID: https://orcid.org/0000-0001-6301-3544)
- Rui Sun (ORCID: https://orcid.org/0000-0002-8484-8089)
- MA Jian-hua
- Ying Wang (ORCID: https://orcid.org/0000-0002-7936-109X)
- Bimin Shi (ORCID: https://orcid.org/0009-0005-0014-8421)
- Chaoming Wu (ORCID: https://orcid.org/0000-0001-6844-6349)
- Xiuhai Su
Institutions
- Ningbo University (CN)
- Fudan University (CN)
- Wenzhou Medical University (CN)
- Soochow University (CN)
- Cangzhou Central Hospital (CN)
- Huzhou Central Hospital (CN)
- People's Hospital of Cangzhou (CN)
- Buchang Pharma (China) (CN)
- Central Hospital of Zibo (CN)
- First Affiliated Hospital of Soochow University (CN)
- Huashan Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1111/dom.70262
- Primary Topic
- Natural Antidiabetic Agents Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00